Skip to main content
. 2018 Apr 16;104(6):1155–1164. doi: 10.1002/cpt.1053

Figure 3.

Figure 3

Observed percent change from baseline in whole blood NE activity after 21 or 28 days of repeated dosing with 10, 25, or 40 mg AZD7986 (a–c) or placebo (d). Each line represents data from one subject. For each subject, baseline NE activity was defined as the median of all observations up to Day 7 after initiation of dosing. Follow‐up NE activity data were not collected in the 10 mg cohort. Placebo data (d) have been pooled from all three cohorts.